Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.4.1 (
phosphodiesterase
)
18,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Several
phosphodiesterase
(
PDE
) inhibitors with the capacity to inhibit the
PDE
IV isoenzyme produce dose-dependent inhibition of IgE-mediated histamine release (HR) from human peripheral leukocytes in vitro. Inhibition reached a maximum after 20 min of preincubation (IC30: 6-30 microM, IC50: 30-80 microM). Motapizone--a potent inhibitor of the isoenzyme
PDE
III--was much less effective, thus giving indirect evidence that
PDE
IV plays a predominant role in the control of cAMP cleavage in human basophils. The inhibiting effect of
PDE
-III/IV-selective compounds on IgE-mediated HR did not exceed the action of
PDE
-IV-selective inhibitors. The inhibition of anti-IgE-induced HR by zardaverine (a
PDE
-III/IV-inhibiting compound) was synergistically enhanced in the combined presence of forskolin or the recently synthesized histamine H2-agonist
FRA
19).
...
PMID:Inhibition of IgE-mediated histamine release from human peripheral leukocytes by selective phosphodiesterase inhibitors. 138 73
